Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 81 - 90 of 173. 10 per page. Page 9.
Advanced SearchPsychosocial Supports in Medication-Assisted Treatment: Recent Evidence and Current Practice
ABSTRACT
This report was included as Appendix B of "Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions." That report's purpose was to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
Westat Printer Friendly Version in PDF Format (3 PDF pages)
Report
Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions
The purpose of this report is to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
As the opioid epidemic has evolved into a national crisis, the need for treatment has increased greatly. Medication-assisted treatment (MAT) is a “whole-patient” approach to the treatment of opioid use disorder (OUD) that combines the use of medications and psychosocial supports, such as therapy, counseling, self-help groups, and case management.
Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions
July 2019
Printer Friendly Version in PDF Format (47 PDF pages)
Choices Matter: Housing Models that May Promote Recovery for Individuals and Families Facing Opioid Use Disorder
ASPE recently completed a research project, conducted by Abt Associates, that explored homelessness and opioid use disorder, along with the evidence base for different models for care. This brief is highlights of findings from the project.
Choice Matters: Housing Models that May Promote Recovery for Individuals and Families Facing Opioid Use Disorder
The purpose of the Opioid Use Disorder, Housing Instability and Housing Options for Recovery project was to help ASPE and HUD describe the housing models available for individuals with Opioid Use Disorder (OUD) who experience housing instability or homelessness.
Public Listing Status of Data-Waivered Providers: Data Brief
Printer Friendly Version in PDF Format (3 PDF pages)
ASPE Issue Brief
Assessing the Costs and Benefits of Extending Coverage of Immunosuppressive Drugs under Medicare
By statute, the majority of patients with end-stage renal disease (ESRD) are eligible for Medicare, regardless of age. Kidney transplantation is ultimately considered the best treatment for ESRD, but ESRD-related eligibility for Medicare coverage extends for only 36 months post-transplant.